Please provide your email address to receive an email when new articles are posted on . Biomind Labs Inc. announced it has received a Controlled Substances License and will begin an 8-month project to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TORONTO, ON / ACCESSWIRE / July 18, 2024 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a leading biotech company dedicated to developing the next-generation ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Biomind Labs Inc. announced the completion of dose ...

Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Crosswinds Holdings Inc. (TSX: CWI) ("Crosswinds") and Biomind Research Corp. ("Biomind" or the "Company") are pleased to announce the ...

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous ...

Biomind Labs Inc. BMNDF, a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of ...

A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20, ...

This press release contains statements that constitute "forward-looking information" ("forward-looking information") within the meaning of the applicable Canadian securities legislation. All ...

“With the conclusion of the dosing sessions, 30 volunteers went through the activities of the proprietary clinical-experimental protocol developed by our scientific team, to verify the safety and ...

TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents ...